Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Other Operating Expenses (2019 - 2024)

Sangamo Therapeutics (SGMO) has 4 years of Other Operating Expenses data on record, last reported at $1.2 million in Q2 2024.

  • For Q2 2024, Other Operating Expenses fell 97.72% year-over-year to $1.2 million; the TTM value through Mar 2025 reached $1.2 million, down 98.84%, while the annual FY2024 figure was $5.5 million, 96.44% down from the prior year.
  • Other Operating Expenses reached $1.2 million in Q2 2024 per SGMO's latest filing, down from $4.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $58.6 million in Q1 2023 and bottomed at $296000.0 in Q4 2023.